## **Core Concept**
IgA nephropathy, also known as Berger's disease, is a kidney disease characterized by the deposition of IgA antibodies in the glomeruli, leading to inflammation. It is a common cause of recurrent hematuria and can progress to kidney failure. The management of IgA nephropathy depends on the severity of symptoms and the level of proteinuria.

## **Why the Correct Answer is Right**
The correct approach for managing IgA nephropathy with mild proteinuria (130 mg/day) and recurrent gross hematuria involves supportive care and monitoring. This typically includes **angiotensin-converting enzyme inhibitors (ACE inhibitors)** or **angiotensin receptor blockers (ARBs)** to reduce proteinuria and slow disease progression, along with close monitoring of renal function and proteinuria. Given the patient's presentation, initiating **ACE inhibitors** (option ) is appropriate as it helps in reducing intraglomerular pressure and proteinuria, which are beneficial in slowing the progression of kidney disease.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is blank and cannot be evaluated.
- **Option B:** This option is blank and cannot be evaluated.
- **Option D:** This option is blank and cannot be evaluated.

## **Clinical Pearl / High-Yield Fact**
A key point to remember in the management of IgA nephropathy is the use of **ACE inhibitors or ARBs** in patients with significant proteinuria (>500 mg/day) or those with hypertension, as these agents have been shown to slow the progression of kidney disease. Even in patients with mild proteinuria like the one described, these agents can still offer renoprotective benefits.

## **Correct Answer:** .